Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim / Rhein, Germany
Trade Register of the Local Court of Mainz, HRB 21063
Identification number for turnover tax: DE 811 138 149
Management Board: Allan Hillgrove, Dr. Michel Pairet, Torsten Rieck
Report an adverse event
If you wish to report an adverse event (AE) after treatment with one of our products, please select your country on the following page. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.
Boehringer Ingelheim local websites
You're now leaving our website...
Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.
Click here for general international information about afatinib for non-small-cell lung cancer treatment.